FitProven
Evidence Breakdown
Based on 8 studies
THE BIGGER QUESTION
Whether this one statement holds is settled above. What to actually do about it is a wider question, weighed across every claim that bears on it.
Evidence map
For & against, at a glance
Meta-Analysis
Pro
Stretton B et al. · 2023Current Sleep Medicine ReportsSystematic review and meta-analysis of Prunus cerasus (tart cherry) and sleep: 277 records screened, 8 trials of low-to-moderate methodological quality included, almost all with 8-30 participants and intervention periods of only 3, 7 or 14 days. Pooled objectively measured sleep efficiency favoured cherry over placebo (effect size 0.63, 95% CI 0.29-0.97, P < 0.01) and objective total sleep time favoured cherry (pooled effect size 1.21, 95% CI 0.83-1.58), but the pooled analyses of subjectively recalled sleep efficiency and total sleep time were not statistically significant. The authors concluded that people may not subjectively notice a benefit even where instruments detect one, and that the evidence base warrants further, better-powered research.
0.55
Systematic review and meta-analysis of Prunus cerasus (tart cherry) and sleep: 277 records screened, 8 trials of low-to-moderate methodological quality included, almost all with 8-30 participants and intervention periods of only 3, 7 or 14 days. Pooled objectively measured sleep efficiency favoured cherry over placebo (effect size 0.63, 95% CI 0.29-0.97, P < 0.01) and objective total sleep time favoured cherry (pooled effect size 1.21, 95% CI 0.83-1.58), but the pooled analyses of subjectively recalled sleep efficiency and total sleep time were not statistically significant. The authors concluded that people may not subjectively notice a benefit even where instruments detect one, and that the evidence base warrants further, better-powered research.
Design Meta-Analysis (1.0) × quality 0.55 = impact 0.55
View sourceCrossover Trial
Pro
Howatson G et al. · 2012European Journal of NutritionRandomised, double-blind, placebo-controlled crossover trial in 20 healthy adults (10 men, 10 women, mean age 26.6 years) who drank 30 mL of Montmorency tart cherry juice concentrate twice daily for 7 days, with sleep measured by actigraphy and urinary 6-sulfatoxymelatonin (the main melatonin metabolite) sampled over 48 hours. Compared with placebo, the cherry condition significantly raised total urinary melatonin and increased time in bed by roughly 25 minutes, total sleep time by roughly 34 minutes, and sleep efficiency by 5-6 percentage points (all P < 0.05); circadian phase timing was unchanged. Participants were healthy sleepers, not insomnia patients, and the trial ran only one week per arm. The Montmorency cherry juice concentrate was supplied by the commercial producer CherryActive (UK).
0.34
Randomised, double-blind, placebo-controlled crossover trial in 20 healthy adults (10 men, 10 women, mean age 26.6 years) who drank 30 mL of Montmorency tart cherry juice concentrate twice daily for 7 days, with sleep measured by actigraphy and urinary 6-sulfatoxymelatonin (the main melatonin metabolite) sampled over 48 hours. Compared with placebo, the cherry condition significantly raised total urinary melatonin and increased time in bed by roughly 25 minutes, total sleep time by roughly 34 minutes, and sleep efficiency by 5-6 percentage points (all P < 0.05); circadian phase timing was unchanged. Participants were healthy sleepers, not insomnia patients, and the trial ran only one week per arm. The Montmorency cherry juice concentrate was supplied by the commercial producer CherryActive (UK).
Design Crossover Trial (0.75) × quality 0.45 = impact 0.34
View sourceSystematic Review
Neutral
Barforoush F et al. · 2025Food Science & NutritionSystematic review (no meta-analysis) of seven interventional studies of tart cherry and sleep, spanning healthy adults, older adults with insomnia and athletes, with doses ranging from 30 mL of concentrate to 480 mL of juice per day and durations from 3 days to 8 weeks. Three trials reported significant improvements in sleep duration, efficiency or onset latency, three reported increased melatonin levels, and two reported reduced inflammatory markers; one included trial (a multi-ingredient cherry-containing supplement) improved only sleep latency and no other sleep parameter. The reviewers concluded the evidence remains "limited and heterogeneous" because of large differences in dose, duration and population, and called for higher-quality trials.
0.45
Systematic review (no meta-analysis) of seven interventional studies of tart cherry and sleep, spanning healthy adults, older adults with insomnia and athletes, with doses ranging from 30 mL of concentrate to 480 mL of juice per day and durations from 3 days to 8 weeks. Three trials reported significant improvements in sleep duration, efficiency or onset latency, three reported increased melatonin levels, and two reported reduced inflammatory markers; one included trial (a multi-ingredient cherry-containing supplement) improved only sleep latency and no other sleep parameter. The reviewers concluded the evidence remains "limited and heterogeneous" because of large differences in dose, duration and population, and called for higher-quality trials.
Design Systematic Review (0.9) × quality 0.50 = impact 0.45
View sourceCrossover Trial
Con
Tucker RM et al. · 2024NutrientsRandomised, placebo-controlled crossover trial in 34 adults with overweight or obesity (mean BMI 32.1) and self-reported sleep problems, who took 500 mg of Montmorency tart cherry powder — a commonly marketed dose — one hour before bed for 14 days per arm with a washout between arms. Nothing improved relative to placebo: objective total sleep time, deep sleep and REM sleep (Zmachine EEG and Fitbit) showed no significant differences, and although Insomnia Severity Index and Pittsburgh Sleep Quality Index scores fell over time in both arms, there was no difference between cherry and placebo; inflammatory markers (TNF-α, IL-6, IL-8, IL-10, IL-17A, CRP) were also unchanged. This is the largest tart-cherry sleep trial to date and it was funded by the Cherry Marketing Institute, the tart cherry growers' trade body.
0.49
Randomised, placebo-controlled crossover trial in 34 adults with overweight or obesity (mean BMI 32.1) and self-reported sleep problems, who took 500 mg of Montmorency tart cherry powder — a commonly marketed dose — one hour before bed for 14 days per arm with a washout between arms. Nothing improved relative to placebo: objective total sleep time, deep sleep and REM sleep (Zmachine EEG and Fitbit) showed no significant differences, and although Insomnia Severity Index and Pittsburgh Sleep Quality Index scores fell over time in both arms, there was no difference between cherry and placebo; inflammatory markers (TNF-α, IL-6, IL-8, IL-10, IL-17A, CRP) were also unchanged. This is the largest tart-cherry sleep trial to date and it was funded by the Cherry Marketing Institute, the tart cherry growers' trade body.
Design Crossover Trial (0.75) × quality 0.65 = impact 0.49
View sourceMeta-Analysis
Pro
Stretton B et al. · 2023Current Sleep Medicine ReportsSystematic review and meta-analysis of Prunus cerasus (tart cherry) and sleep: 277 records screened, 8 trials of low-to-moderate methodological quality included, almost all with 8-30 participants and intervention periods of only 3, 7 or 14 days. Pooled objectively measured sleep efficiency favoured cherry over placebo (effect size 0.63, 95% CI 0.29-0.97, P < 0.01) and objective total sleep time favoured cherry (pooled effect size 1.21, 95% CI 0.83-1.58), but the pooled analyses of subjectively recalled sleep efficiency and total sleep time were not statistically significant. The authors concluded that people may not subjectively notice a benefit even where instruments detect one, and that the evidence base warrants further, better-powered research.
0.55
Systematic review and meta-analysis of Prunus cerasus (tart cherry) and sleep: 277 records screened, 8 trials of low-to-moderate methodological quality included, almost all with 8-30 participants and intervention periods of only 3, 7 or 14 days. Pooled objectively measured sleep efficiency favoured cherry over placebo (effect size 0.63, 95% CI 0.29-0.97, P < 0.01) and objective total sleep time favoured cherry (pooled effect size 1.21, 95% CI 0.83-1.58), but the pooled analyses of subjectively recalled sleep efficiency and total sleep time were not statistically significant. The authors concluded that people may not subjectively notice a benefit even where instruments detect one, and that the evidence base warrants further, better-powered research.
Design Meta-Analysis (1.0) × quality 0.55 = impact 0.55
View sourceCrossover Trial
Pro
Howatson G et al. · 2012European Journal of NutritionRandomised, double-blind, placebo-controlled crossover trial in 20 healthy adults (10 men, 10 women, mean age 26.6 years) who drank 30 mL of Montmorency tart cherry juice concentrate twice daily for 7 days, with sleep measured by actigraphy and urinary 6-sulfatoxymelatonin (the main melatonin metabolite) sampled over 48 hours. Compared with placebo, the cherry condition significantly raised total urinary melatonin and increased time in bed by roughly 25 minutes, total sleep time by roughly 34 minutes, and sleep efficiency by 5-6 percentage points (all P < 0.05); circadian phase timing was unchanged. Participants were healthy sleepers, not insomnia patients, and the trial ran only one week per arm. The Montmorency cherry juice concentrate was supplied by the commercial producer CherryActive (UK).
0.34
Randomised, double-blind, placebo-controlled crossover trial in 20 healthy adults (10 men, 10 women, mean age 26.6 years) who drank 30 mL of Montmorency tart cherry juice concentrate twice daily for 7 days, with sleep measured by actigraphy and urinary 6-sulfatoxymelatonin (the main melatonin metabolite) sampled over 48 hours. Compared with placebo, the cherry condition significantly raised total urinary melatonin and increased time in bed by roughly 25 minutes, total sleep time by roughly 34 minutes, and sleep efficiency by 5-6 percentage points (all P < 0.05); circadian phase timing was unchanged. Participants were healthy sleepers, not insomnia patients, and the trial ran only one week per arm. The Montmorency cherry juice concentrate was supplied by the commercial producer CherryActive (UK).
Design Crossover Trial (0.75) × quality 0.45 = impact 0.34
View sourceSystematic Review
Neutral
Barforoush F et al. · 2025Food Science & NutritionSystematic review (no meta-analysis) of seven interventional studies of tart cherry and sleep, spanning healthy adults, older adults with insomnia and athletes, with doses ranging from 30 mL of concentrate to 480 mL of juice per day and durations from 3 days to 8 weeks. Three trials reported significant improvements in sleep duration, efficiency or onset latency, three reported increased melatonin levels, and two reported reduced inflammatory markers; one included trial (a multi-ingredient cherry-containing supplement) improved only sleep latency and no other sleep parameter. The reviewers concluded the evidence remains "limited and heterogeneous" because of large differences in dose, duration and population, and called for higher-quality trials.
0.45
Systematic review (no meta-analysis) of seven interventional studies of tart cherry and sleep, spanning healthy adults, older adults with insomnia and athletes, with doses ranging from 30 mL of concentrate to 480 mL of juice per day and durations from 3 days to 8 weeks. Three trials reported significant improvements in sleep duration, efficiency or onset latency, three reported increased melatonin levels, and two reported reduced inflammatory markers; one included trial (a multi-ingredient cherry-containing supplement) improved only sleep latency and no other sleep parameter. The reviewers concluded the evidence remains "limited and heterogeneous" because of large differences in dose, duration and population, and called for higher-quality trials.
Design Systematic Review (0.9) × quality 0.50 = impact 0.45
View sourceCrossover Trial
Con
Tucker RM et al. · 2024NutrientsRandomised, placebo-controlled crossover trial in 34 adults with overweight or obesity (mean BMI 32.1) and self-reported sleep problems, who took 500 mg of Montmorency tart cherry powder — a commonly marketed dose — one hour before bed for 14 days per arm with a washout between arms. Nothing improved relative to placebo: objective total sleep time, deep sleep and REM sleep (Zmachine EEG and Fitbit) showed no significant differences, and although Insomnia Severity Index and Pittsburgh Sleep Quality Index scores fell over time in both arms, there was no difference between cherry and placebo; inflammatory markers (TNF-α, IL-6, IL-8, IL-10, IL-17A, CRP) were also unchanged. This is the largest tart-cherry sleep trial to date and it was funded by the Cherry Marketing Institute, the tart cherry growers' trade body.
0.49
Randomised, placebo-controlled crossover trial in 34 adults with overweight or obesity (mean BMI 32.1) and self-reported sleep problems, who took 500 mg of Montmorency tart cherry powder — a commonly marketed dose — one hour before bed for 14 days per arm with a washout between arms. Nothing improved relative to placebo: objective total sleep time, deep sleep and REM sleep (Zmachine EEG and Fitbit) showed no significant differences, and although Insomnia Severity Index and Pittsburgh Sleep Quality Index scores fell over time in both arms, there was no difference between cherry and placebo; inflammatory markers (TNF-α, IL-6, IL-8, IL-10, IL-17A, CRP) were also unchanged. This is the largest tart-cherry sleep trial to date and it was funded by the Cherry Marketing Institute, the tart cherry growers' trade body.
Design Crossover Trial (0.75) × quality 0.65 = impact 0.49
View sourceShowing the 4 strongest of 8 studies. Tap any node to expand its detail.
Evidence
PRO (4)
PRO Meta-Analysis0.55 Stretton B, Eranki A et al. (2023)
Objective sleep efficiency favoured tart cherry over placebo (ES 0.63, 95% CI 0.29-0.97, P < 0.01) and objective total sleep time favoured cherry (ES 1.21, 95% CI 0.83-1.58); pooled SUBJECTIVE sleep efficiency and total sleep time were not significant
Systematic review and meta-analysis of Prunus cerasus (tart cherry) and sleep: 277 records screened, 8 trials of low-to-moderate methodological quality included, almost all with 8-30 participants and intervention periods of only 3, 7 or 14 days. Pooled objectively measured sleep efficiency favoured cherry over placebo (effect size 0.63, 95% CI 0.29-0.97, P < 0.01) and objective total sleep time favoured cherry (pooled effect size 1.21, 95% CI 0.83-1.58), but the pooled analyses of subjectively recalled sleep efficiency and total sleep time were not statistically significant. The authors concluded that people may not subjectively notice a benefit even where instruments detect one, and that the evidence base warrants further, better-powered research.
Weighted 0.55 — k=8 trials from 277 records; no pooled participant total is reported, so sample_size is omitted. Revised down from the previous 0.70. The design class is meta-analysis, but the inputs are weak: the authors themselves rate the included trials low-to-moderate methodological quality, nearly all had only 8-30 participants, and interventions ran just 3, 7 or 14 days -- with k=8 that is a high publication-bias risk. The objective/subjective split is itself a warning sign: people did not notice the benefit the instruments detected. No competing interests declared and no research grant (open-access fee via a library agreement).
Current Sleep Medicine Reports
PRO Crossover Trialn=200.45 Howatson G, Bell PG et al. (2012)
+34 min total sleep time, +25 min time in bed, sleep efficiency +5-6 percentage points, and raised urinary melatonin (all P<0.05)
Randomised, double-blind, placebo-controlled crossover trial in 20 healthy adults (10 men, 10 women, mean age 26.6 years) who drank 30 mL of Montmorency tart cherry juice concentrate twice daily for 7 days, with sleep measured by actigraphy and urinary 6-sulfatoxymelatonin (the main melatonin metabolite) sampled over 48 hours. Compared with placebo, the cherry condition significantly raised total urinary melatonin and increased time in bed by roughly 25 minutes, total sleep time by roughly 34 minutes, and sleep efficiency by 5-6 percentage points (all P < 0.05); circadian phase timing was unchanged. Participants were healthy sleepers, not insomnia patients, and the trial ran only one week per arm. The Montmorency cherry juice concentrate was supplied by the commercial producer CherryActive (UK).
Weighted 0.45 — Only 20 healthy sleepers - not insomnia patients - and each arm ran just 7 days. The crossover design with objective actigraphy and urinary 6-sulfatoxymelatonin is a genuine strength, but the product was supplied by its commercial producer and the paper carries no conflict-of-interest statement - an industry-supplied positive result.
Funding: CherryActive (UK) supplied the cherry juice concentrate; no funding statement in the paper
European Journal of Nutrition
PRO Crossover Trialn=8CONFLICTED0.30 Losso JN, Finley JW et al. (2018)
+84 min polysomnography-measured sleep time (P=0.018) and improved PSQI sleep efficiency (P=0.03); kynurenine-to-tryptophan ratio and prostaglandin E2 fell
Placebo-controlled balanced crossover pilot study in adults over 50 with insomnia: 11 were randomised and only 8 completed the insomnia analysis, drinking 240 mL of tart cherry juice twice daily for 2 weeks against a 2-week placebo arm separated by a 2-week washout. In those 8 completers, polysomnography-measured sleep time increased by 84 minutes (P = 0.018) and Pittsburgh Sleep Quality Index sleep efficiency improved (P = 0.03); the serum kynurenine-to-tryptophan ratio and prostaglandin E2 fell, and in vitro the cherry procyanidin B-2 inhibited indoleamine 2,3-dioxygenase, suggesting the mechanism is increased tryptophan availability rather than the cherry's own melatonin. The 84-minute figure is by far the largest reported in this literature and rests on 8 people.
Weighted 0.30 — 11 randomised, only 8 completed the insomnia analysis (3 excluded after polysomnography revealed sleep apnoea). The Cherry Marketing Institute — the tart-cherry growers' trade body — both funded the trial and supplied the juice, yet the paper declares no conflicts of interest. An industry-funded positive result resting on 8 people; the authors themselves call it an underpowered pilot. The 84-minute effect is far larger than anything else in this literature, which is itself a warning sign rather than a strength.
Funding: "This trial was supported by the Cherry Marketing Institute which had nothing to do with the design of the trial." Additional support from NIH grants P50AT002776 (NCCAM/ODS), 2P30DK072476 (NIDDK) and 1U54GM104940 (NIGMS). The paper states "Conflicts of interest: none". — the funder profits from this result.
American Journal of Therapeutics
PRO Double-Blind RCTn=190.30 Chung J, Choi M et al. (2022)
Group-by-time interactions for total time in bed (P = 0.015), wake after sleep onset (P = 0.044) and movement index (P = 0.031); NO interaction for salivary melatonin or cortisol
Double-blind randomised controlled trial in 19 elite female field hockey players (10 tart cherry, 9 placebo) who drank 30 mL of Montmorency tart cherry juice five times over 48 hours following an intermittent exhaustive exercise protocol, with sleep measured by actigraphy. Significant group-by-time interactions appeared for total time in bed (P = 0.015), wake after sleep onset (P = 0.044) and movement index (P = 0.031), but there was no significant interaction for salivary melatonin or cortisol — the proposed hormonal mechanism was not detected. The trial is very small, very short, and in a specific post-exercise athletic population rather than in people with sleep complaints.
Weighted 0.30 — Only 19 players (10 vs 9) over a 48-hour post-exercise window — severely underpowered, and in elite female athletes recovering from an exhaustive protocol rather than in people with sleep complaints, so it is indirect for any general sleep claim. Independently funded and double-blind, which is why it is not lower, but the proposed melatonin mechanism was explicitly not detected.
Funding: Dongguk University Research Fund (2022); authors declared no competing interest
International Journal of Environmental Research and Public Health
AGAINST (1)
AGAINST Crossover Trialn=34AGAINST FUNDER0.65 Tucker RM, Kim N et al. (2024)
No difference vs placebo in total sleep time, deep sleep, REM, Insomnia Severity Index, PSQI, or TNF-alpha/IL-6/IL-8/IL-10/IL-17A/CRP
Randomised, placebo-controlled crossover trial in 34 adults with overweight or obesity (mean BMI 32.1) and self-reported sleep problems, who took 500 mg of Montmorency tart cherry powder — a commonly marketed dose — one hour before bed for 14 days per arm with a washout between arms. Nothing improved relative to placebo: objective total sleep time, deep sleep and REM sleep (Zmachine EEG and Fitbit) showed no significant differences, and although Insomnia Severity Index and Pittsburgh Sleep Quality Index scores fell over time in both arms, there was no difference between cherry and placebo; inflammatory markers (TNF-α, IL-6, IL-8, IL-10, IL-17A, CRP) were also unchanged. This is the largest tart-cherry sleep trial to date and it was funded by the Cherry Marketing Institute, the tart cherry growers' trade body.
Weighted 0.65 — n=34 analysed, 14 days per arm — the largest and longest tart-cherry sleep trial to date. Funded by the tart cherry growers' trade body, but the result is null, so sponsor bias runs against the finding rather than toward it, which makes the null more credible rather than less. Modest n and a single 500 mg dose keep it short of definitive.
Funding: Cherry Marketing Institute — this result runs against the funder's own interest, which strengthens it.
Nutrients
NEUTRAL (3)
NEUTRAL In VitroINDUSTRY0.65 Burkhardt S, Tan DX et al. (2001)
Montmorency cherries 13.46 +/- 1.10 ng melatonin per gram vs Balaton 2.06 +/- 0.17 ng/g (~6x); a 100 g serving supplies roughly 1.3 micrograms, three orders of magnitude below a 1-5 mg supplement
Analytical (HPLC) quantification of melatonin in two tart cherry cultivars, not a human trial. Montmorency cherries contained 13.46 ± 1.10 ng of melatonin per gram of fruit, about six times more than Balaton cherries (2.06 ± 0.17 ng/g); orchard location and harvest timing did not meaningfully change the content. At that concentration a 100 g serving of Montmorency cherries supplies roughly 1.3 micrograms of melatonin — three orders of magnitude below the 1-5 mg found in a typical melatonin supplement — which is the central quantitative problem for the claim that tart cherries work by delivering dietary melatonin.
Weighted 0.65 — Analytical HPLC quantification of fruit, not a trial — no participants, so no sample size applies. The measurement itself is precise and sampled across orchards and harvest timings, and the finding (melatonin content is minuscule) cuts against the funder's interest, which raises confidence. Discounted for being funded by the tart-cherry industry and for being an indirect, mechanism-only input to any human claim.
Funding: Cherry Marketing Institute
Journal of Agricultural and Food Chemistry
NEUTRAL Systematic Review0.50 Barforoush F, Ebrahimi S et al. (2025)
Of 7 interventional trials, 3 reported significant improvements in sleep duration, efficiency or onset latency and 3 reported increased melatonin; the reviewers judged the evidence limited and heterogeneous
Systematic review (no meta-analysis) of seven interventional studies of tart cherry and sleep, spanning healthy adults, older adults with insomnia and athletes, with doses ranging from 30 mL of concentrate to 480 mL of juice per day and durations from 3 days to 8 weeks. Three trials reported significant improvements in sleep duration, efficiency or onset latency, three reported increased melatonin levels, and two reported reduced inflammatory markers; one included trial (a multi-ingredient cherry-containing supplement) improved only sleep latency and no other sleep parameter. The reviewers concluded the evidence remains "limited and heterogeneous" because of large differences in dose, duration and population, and called for higher-quality trials.
Weighted 0.50 — k=7 interventional studies; no pooled participant total is reported, so sample_size is omitted. No meta-analysis was possible because of the spread in dose (30 mL of concentrate to 480 mL of juice), duration (3 days to 8 weeks) and population (healthy adults, older insomniacs, athletes). Independent, academically funded, and the reviewers themselves call the evidence limited — a narrative-grade synthesis carrying the systematic_review label, hence the 0.50 multiplier.
Funding: Student Research Committee, Kerman University of Medical Sciences, Iran (grant 403000836)
Food Science & Nutrition
NEUTRAL Crossover Trialn=15INDUSTRY0.40 Pigeon WR, Carr M et al. (2010)
Wake after sleep onset fell by roughly 17 min/night (from a baseline near 79 min) and Insomnia Severity Index improved vs placebo; sleep latency, total sleep time and sleep efficiency did not differ (d ≈ 0.17-0.86)
Randomised, double-blind, placebo-controlled crossover pilot study in 15 older adults with chronic insomnia, who drank 8 oz of a tart cherry juice blend morning and evening for 2 weeks, with a 2-week washout before crossing over to a matched non-cherry placebo drink. Cherry juice significantly reduced wake after sleep onset (roughly 17 minutes less per night, from a baseline near 79 minutes) and Insomnia Severity Index scores versus placebo, but sleep latency, total sleep time and sleep efficiency did not differ significantly from placebo; effect sizes ranged from negligible to moderate (d ≈ 0.17-0.86). The authors themselves noted the benefit was "considerably less than" that of hypnotic drugs or cognitive-behavioural therapy for insomnia. The study was funded in its entirety by CherryPharm, Inc., the manufacturer of the tart cherry juice tested.
Weighted 0.40 — n=15 completers, 2 weeks per arm. The design is the strength — randomised, double-blind, placebo-controlled crossover — but the sample is a pilot, most sleep outcomes were null, and the trial was funded in its entirety by the manufacturer of the product tested. An industry-funded positive result at n=15 is the weakest combination there is, hence 0.40 despite the crossover design.
Funding: CherryPharm, Inc. — the manufacturer of the tart cherry juice tested
Journal of Medicinal Food